it isn’t clear but the presentation suggests Merck is more than a drug supplier. It also appears to me that IMM is targeting NSCLC and breast cancer more than head and neck cancer which is why they had a slide showing relative market size
I wished we had a clear pathway to fruition in May but you have to careful what you wish for. Despite the dilution I think we are in better shape now than before. We have a pathway. The biotech companies I have owned in the past showed their greatest share price increases when phase 3 trials are started.
it isn’t clear but the presentation suggests Merck is more than...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.040(11.9%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.0¢ | 28.0¢ | $7.278M | 23.75M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 53192 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 41048 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |